Alimera Sciences (ALIM) Stock Forecast, Price & News

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Alimera Sciences in the last twelve months. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" ALIM shares.
View ALIM analyst ratings or view top-rated stocks.

2 brokerages have issued 12 month price targets for Alimera Sciences' stock. Their ALIM share price forecasts range from $4.50 to $8.00. On average, they predict the company's share price to reach $5.83 in the next year. This suggests a possible upside of 116.0% from the stock's current price.
View analysts price targets for ALIM or view top-rated stocks among Wall Street analysts.

Alimera Sciences' stock was trading at $2.71 on January 1st, 2023. Since then, ALIM shares have decreased by 0.4% and is now trading at $2.70.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Wednesday, July 26th 2023.
View our ALIM earnings forecast.

Alimera Sciences, Inc. (NASDAQ:ALIM) announced its quarterly earnings data on Wednesday, October, 27th. The biopharmaceutical company reported ($0.60) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.52) by $0.08. The biopharmaceutical company had revenue of $12.15 million for the quarter, compared to analyst estimates of $12.30 million. During the same quarter in the prior year, the business earned ($0.12) earnings per share.

Shares of Alimera Sciences reverse split before market open on Friday, November 15th 2019. The 1-15 reverse split was announced on Thursday, November 7th 2019. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, November 14th 2019. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

2 employees have rated Alimera Sciences Chief Executive Officer Rick Eiswirth on Glassdoor.com. Rick Eiswirth has an approval rating of 100% among the company's employees. This puts Rick Eiswirth in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other Alimera Sciences investors own include EyePoint Pharmaceuticals (EYPT), OPKO Health (OPK), VBI Vaccines (VBIV), Aldeyra Therapeutics (ALDX), Advanced Micro Devices (AMD), Amarin (AMRN), AngloGold Ashanti (AU), SSR Mining (SSRM), ADMA Biologics (ADMA) and Cellectar Biosciences (CLRB).

Alimera Sciences trades on the NASDAQ under the ticker symbol "ALIM."

Shares of ALIM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of ALIM stock can currently be purchased for approximately $2.70.

Alimera Sciences (NASDAQ:ALIM) has a market capitalization of $19.98 million and generates $54.13 million in revenue each year. The biopharmaceutical company earns $-18,110,000.00 in net income (profit) each year or ($2.45) on an earnings per share basis.

The company employs 145 workers across the globe.

Alimera Sciences' mailing address is 6120 WINDWARD PARKWAY STE 290, ALPHARETTA GA, 30005. The official website for the company is www.alimerasciences.com. The biopharmaceutical company can be reached via phone at (678) 990-5740, via email at scottg@coreir.com, or via fax at 678-990-5744.